Study Watch with Irregular Pulse Monitor (Home) vs TeraRecon Cardiac.Chambers.MR

The Verily Study Watch is designed to record, store, and transfer single-channel ECG rhythms and irregular pulse data. This data is transferred from the Study Watch to a Study Hub via USB, and then to Verily's cloud server for storage, where it can be viewed by a healthcare professional (HCP) using a web portal. The patient does not have direct access to independently view these data. Verily aims to create clinical solutions that consider clinician workflows and care pathways, and is exploring how to leverage the Study Watch with other services to support continuous monitoring and data analytics.

For irregular pulse detection, the Verily Study Watch's PPG-based algorithm has demonstrated a per-interval sensitivity of 96.1% and specificity of 98.1% for continuous monitoring in a home-use setting, using Zio Patch ECG data as ground truth. The device has been found to be very accurate at identifying atrial fibrillation in participants. Beyond AFib, the Study Watch collects data from multiple physiological sensors, including heart rate, electrodermal activity, and inertial movements, which have been used in research for conditions like Parkinson's disease and heart failure to derive digital biomarkers.

TeraRecon Cardiac.Chambers.MR automatically segments cardiac chambers from DICOM-compliant MR images and outputs the results as DICOM files, which can be utilized by other DICOM-compliant systems like PACS or TeraRecon's Intuition system. This AI-driven automation is designed to reduce post-processing time and accelerate workflows by providing complementary insights and completed pre-work, aiming to enhance diagnostic precision and streamline processes. The system supports standardized cardiac imaging workflows, improving efficiency and consistency in day-to-day cardiac MR analysis.

While specific validation metrics for TeraRecon Cardiac.Chambers.MR were not detailed in the provided information, related deep learning frameworks for cardiac MRI segmentation have achieved high overall performance, with reported accuracy of 0.9913 and a mean Dice score of 0.8968 across test slices for LV, RV, and myocardium segmentation. TeraRecon's Intuition platform, which includes Cardiac.Chambers.MR functionality, offers volumetric analysis of ejection fraction and LV/RV inner and outer contour detection. The system is designed to provide seamless and effortless clinical software updates for access to the latest features, which suggests ongoing maintenance and improvement of its algorithms.

For the Verily Study Watch, data stored on the device is encrypted before being uploaded to the cloud. Verily adheres to industry-recognized frameworks and standards, commissioning independent cybersecurity audits, and implements multiple layers of controls including strong encryption (in-transit & at-rest) and tightly restricted, monitored role-based access. For TeraRecon Cardiac.Chambers.MR, while specific audit trail features are not detailed, TeraRecon describes strict data confidentiality procedures for PHI and aims to assist customers with data security compliance. The platform also supports in-depth monitoring and analytics for operational workflows.

For the Verily Study Watch, the device is designed to be unobtrusive and easy for patients to wear, and physicians have found it easy to explain its use to patients, leading to high usage in studies. Verily provides comprehensive clinical trial support across regulatory, development, operations, and compliance. For TeraRecon Cardiac.Chambers.MR, the platform prioritizes clinician satisfaction with intuitive workflows and customizable templates, aiming for ease of use and high adoption rates. TeraRecon offers specialized clinical tools and aims to streamline processes, suggesting a focus on reducing the learning curve. TeraRecon also provides user manuals for its products.

For the Verily Study Watch, its design for scalable collection of rich and complex datasets across clinical and observational studies, along with on-device data encryption and cloud-based processing, supports large population studies. Verily has experience in multi-site studies, such as the Personalized Parkinson Project, and is exploring broader deployment across Europe and North America. For TeraRecon Cardiac.Chambers.MR, its deployment as a containerized application and availability on a robust cloud-based SaaS platform (TeraRecon AV) offers benefits like ultimate scalability, adaptive compute and storage, and seamless software updates, which are crucial for multi-site deployment and standardization.